🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Kilitch Drugs (India) Limited KILITCH NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://kilitch.com

Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally. The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, anticoagulant, narcotic, oncology, ophthalmic, antifungal, corticosteroid, anticoagulant, and other applications, as well as vaccines, veterinary products, iron supplements for anemia, Klavmox, and Onecef. It also provides oral formulations, including tablets, capsules, dry syrup, and oral powder for antibiotic, anti-diabetic, cardiovascular, and other areas; effervescent tablets and powders, such as Roipar, Duregra, and Roivit; and nutritional products, including Celtine. In addition, the company offers cosmetics, which include oil, lotion, liquid to cream, paste in skin, and personal and hair care products; herbal products for use in sore throat and prostate problems, as well as a supplement for diabetes, obesity, libido, and other conditions; ortho rehabilitation and implants; and medical devices comprising C-Seal, a skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Further, it provides PH-7 which reduces acid content of the stomach; SRO kit for treating childhood diarrhea; 9-VIT for use in surgery, extensive burns, fractures, and other trauma; and HPURE for sore throat and cough. The company exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.

READ MORE ›
₹182.39
-14.95% 1Y

Market & Price

Market Cap
₹637.66 Cr
Current Price
₹182.39
High / Low (52W)
₹241.72 / ₹124.45
Beta
0.14

Valuation

Stock P/E
20.45
Industry PE
37.60
Forward P/E
11.92
PEG Ratio
-
Book Value
₹81.67
Price to Book
2.23
P/S
2.71
EV/EBITDA
17.53
Dividend Yield
-

Profitability & Returns

ROCE
13.15%
ROE
12.36%
ROA
5.35%
Profit Margin
12.81%
Op Margin
23.62%
EPS (Latest Qtr)
₹4.24
EPS (TTM)
₹8.92

Balance Sheet & Liquidity

Debt/Equity
0.32
Quick Ratio
1.55
Current Ratio
1.83
Debt
₹88.71 Cr
Total Assets
₹457.75 Cr
Current Assets
₹222.20 Cr
Working Capital
₹100.60 Cr

Ownership

Promoter Holding
72.22%
Chg in Prom Hold
-
FII / Inst Holding
0.00%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹641.72 Cr
Total Revenue (TTM)
₹235.47 Cr
EBITDA
₹36.60 Cr
Free Cash Flow
₹-88.82 Cr
Operating Cash Flow
₹23.96 Cr
Shares Outstanding
₹3.50 Cr
Gross Margin
46.44%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
19.25%
Profit 5Y
42.40%
Revenue (YoY)
46.30%
Earnings (YoY)
26.50%

PROS

  • Compounding revenue at 19.2% over 5 years.
  • Profit CAGR of 42.4% over 5 years.

CONS

  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 KILITCH Kilitch Drugs (India) Limited NSEPHARMA 182.39 20.45 ₹637.66 Cr - 13.15% 12.36% 19.25% 42.40%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,799.20 37.59 ₹4.32 L Cr 0.92% 17.94% 14.72% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 6,667.00 68.97 ₹1.77 L Cr 0.45% 18.96% 16.19% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,410.80 68.96 ₹1.49 L Cr 0.86% 9.06% 16.98% 13.27% 20.21%
5 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,401.00 29.16 ₹1.13 L Cr 0.93% 14.88% 11.74% 7.23% 11.45%
6 DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA 1,303.50 25.90 ₹1.09 L Cr 0.61% 14.00% 11.83% 10.96% -2.35%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,077.70 21.51 ₹1.08 L Cr 0.09% 19.24% 18.32% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,267.70 19.49 ₹1.04 L Cr 0.53% 28.42% 26.91% 19.10% 131.46%
9 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,375.60 51.29 ₹98,090.71 Cr 0.08% 13.78% 12.45% 17.73% 14.28%
Ad space

Quarterly Results

Figures in INR.

Metric Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -56.17 Cr61.23 Cr43.14 Cr48.92 Cr53.81 Cr89.60 Cr
Cost of Revenue -32.76 Cr28.70 Cr25.46 Cr26.36 Cr30.89 Cr44.15 Cr
Gross Profit -23.41 Cr32.53 Cr17.68 Cr22.56 Cr22.92 Cr45.45 Cr
Operating Expenses -15.48 Cr18.78 Cr15.26 Cr18.38 Cr17.71 Cr24.29 Cr
Operating Income -7.93 Cr13.75 Cr2.42 Cr4.18 Cr5.21 Cr21.16 Cr
EBITDA -10.46 Cr16.29 Cr5.82 Cr11.70 Cr7.68 Cr22.64 Cr
Interest Expense -1.40 Cr1.60 Cr1.53 Cr1.44 Cr1.15 Cr1.44 Cr
Pretax Income -8.25 Cr13.84 Cr3.45 Cr9.40 Cr5.60 Cr20.21 Cr
Tax Provision -2.64 Cr3.63 Cr1.19 Cr1.36 Cr1.28 Cr5.33 Cr
Net Income -5.96 Cr10.40 Cr3.03 Cr8.19 Cr4.43 Cr14.52 Cr
Diluted EPS 2.681.856.470.922.481.254.24

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -138.86 Cr153.61 Cr198.32 Cr235.47 Cr
Cost of Revenue -77.13 Cr80.47 Cr104.58 Cr126.13 Cr
Gross Profit -61.72 Cr73.14 Cr93.74 Cr109.34 Cr
Operating Expenses -47.37 Cr52.05 Cr65.38 Cr76.37 Cr
Operating Income -14.35 Cr21.08 Cr28.35 Cr32.98 Cr
EBITDA -20.48 Cr28.63 Cr42.63 Cr47.84 Cr
Interest Expense -4.92 Cr5.93 Cr5.04 Cr5.56 Cr
Pretax Income -12.01 Cr19.35 Cr34.47 Cr38.65 Cr
Tax Provision -3.73 Cr5.78 Cr9.53 Cr9.15 Cr
Net Income -10.45 Cr14.60 Cr26.70 Cr30.17 Cr
Diluted EPS -3.284.4916.608.91

Compounded Sales Growth

5 Years:19.25%
1 Year:46.30%

Compounded Profit Growth

5 Years:42.40%
1 Year:26.50%

Stock Price Performance

1 Year:-14.95%
6 Months:-1.06%
3 Months:+16.23%
1 Month:+18.60%

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -219.52 Cr240.06 Cr312.78 Cr457.75 Cr
Current Assets -126.40 Cr145.99 Cr173.92 Cr222.20 Cr
Cash & Equivalents -19.79 Cr18.91 Cr9.75 Cr15.77 Cr
Inventory -2.41 Cr5.58 Cr21.58 Cr11.52 Cr
Receivables -54.29 Cr63.22 Cr84.74 Cr120.18 Cr
Total Liabilities -68.94 Cr64.39 Cr112.33 Cr180.88 Cr
Current Liabilities -68.87 Cr64.22 Cr84.31 Cr121.60 Cr
Long Term Debt --027.77 Cr58.60 Cr
Total Debt -22.19 Cr31.65 Cr49.42 Cr88.71 Cr
Total Equity -151.60 Cr176.29 Cr202.33 Cr279.65 Cr
Shares Outstanding -3.18 Cr3.29 Cr3.29 Cr3.50 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -2.59 Cr-1.53 Cr17.54 Cr23.96 Cr
Investing Cash Flow -7.92 Cr-8.16 Cr-39.95 Cr-100.44 Cr
Financing Cash Flow --71.63 L8.81 Cr13.24 Cr82.45 Cr
Capital Expenditure --3.81 Cr-6.45 Cr-46.87 Cr-99.51 Cr
Free Cash Flow --1.23 Cr-7.99 Cr-29.33 Cr-75.55 Cr
Net Change in Cash -9.78 Cr-88.45 L-9.16 Cr5.97 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -44.5%47.6%47.3%46.4%
Operating Margin % -10.3%13.7%14.3%14.0%
Net Margin % -7.5%9.5%13.5%12.8%
ROE % -6.9%8.3%13.2%10.8%
ROCE % -9.5%12.0%12.4%9.8%

Shareholding Pattern

Insiders
72.22%
Institutions
0.00%
Public Float
0.00%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for KILITCH

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks